A5045641506- Cancer Immunotherapy and Biomarkers
- Bone health and treatments
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Bone Metabolism and Diseases
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Fibroblast Growth Factor Research
- Prostate Cancer Treatment and Research
- Cancer, Stress, Anesthesia, and Immune Response
- RNA Research and Splicing
- Parathyroid Disorders and Treatments
- Colorectal Cancer Surgical Treatments
- Metastasis and carcinoma case studies
- Pharmacovigilance and Adverse Drug Reactions
- Economic and Financial Impacts of Cancer
- S100 Proteins and Annexins
- Pharmacological Receptor Mechanisms and Effects
- Heat shock proteins research
- Venous Thromboembolism Diagnosis and Management
- Drug-Induced Adverse Reactions
Hospital de Santa Maria
2015-2025
Centro Hospitalar Lisboa Norte
2015-2020
Royal Marsden Hospital
2019
Hospital of St. Francis Xavier
2017
Universitat Rovira i Virgili
2002
Immunotherapy has revolutionized advanced melanoma treatment. Several prognostic factors have been studied to predict survival in this setting. We aimed develop a score. A multicentre, retrospective cohort study was conducted including patients with who started anti-programmed cell death protein 1 (PD-1) monotherapy between January 2016 and October 2019 ≤2 prior treatment lines. The endpoint overall (OS). Univariate multivariate Cox regression identified independent factors, 95% confidence...
The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as potential therapeutic target. In this study, the authors aimed to assess impact of serum FGF23 levels prognosis patients with cancer bone metastases from solid tumors. A cohort 112 metastatic disease were treated bone-targeted agents (BTA). Serum baseline was quantified by ELISA dichotomized FGF23high FGF23low groups. Additionally, association between overall survival (OS) time...
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock that has been implicated in all hallmarks of cancer. Elevated level was associated with poor prognosis several types cancers, including breast cancer (BC), where it marker decreased overall survival (OS) and distant metastasis-free across subtypes. also secreted by different cell may act as an extracellular mitogen; however the pathological implications form (sYB-1) are unknown. Our purpose to retrospectively evaluate association...
Cervical cancer (CC) is one of the acquired immunodeficiency syndrome (AIDS) defining diseases and human virus (HIV) infection thought to relate with increased acute toxicity chemoradiotherapy (CRT). We investigated effect HIV status in incidence neutropenia associated cisplatin-based CRT for CC its impact treatment completion. This a single-center retrospective cohort study. Data collection was performed all consecutive stage Ib-IV women treated from 2012 2016, known status. Sixty-one...
658 Background: We previously stratified CRC into five intrinsic gene expression subtypes (CRCAssigner) and four consensus molecular (CMS1-4) using expensive time-consuming microarray/RNAseq platforms. Recently, we developed a low-cost (NanoCRC) assay nCounter platform (NanoString Technology) robust signatures to classify individual samples both CRCAssigner CMS subtypes. Here, tested the assays formalin-fixed paraffin-embedded (FFPE) patient from Royal Marsden Hospital. Given increased...
Receptor activator of NF-kB (RANK) pathway regulates bone remodeling and is involved in breast cancer (BC) progression. Genetic polymorphisms affecting RANK-ligand (RANKL) osteoprotegerin (OPG) have been previously associated with BC risk metastasis (BM)-free survival, respectively. In this study we conducted a retrospective analysis the association five missense RANK SNPs clinical characteristics outcomes patients BM. SNP rs34945627 had an allelic frequency 12.5% patients, compared to 1.2%...
135 Background: Immunotherapy (IO) has changed the disease course of metastatic malignant melanoma (mMM). Prognostic biomarkers are lacking, but high neutrophil-lymphocyte ratio (NLR) been correlated with poor outcome. Lymphocyte-monocyte (LMR) and platelet-lymphocyte (PLR) also readily available. This study aimed to investigate prognostic value NLR, LMR PLR. Methods: Retrospective cohort mMM patients (pts) treated anti PD-1 blockade in 2 centers, between Jan ’13-Aug ’18. Baseline 6-week (6...
Searchable abstracts of presentations at key conferences on calcified tissues ISSN 2052-1219 (online)
e15743 Background: NG is a standard 1 st line treatment for APC. Although recommended in 2 nd after FOLFIRINOX, there little evidence of its efficacy, tolerability and markers efficacy. Methods: We performed multicenter retrospective cohort study, including patients (pts) with APC from 5 centers Portugal treated FOLFIRINOX 01/2013-12/2016. collected demographic, clinicopathological characteristics data. used descriptive statistics, Kaplan-Meier methods Cox proportional hazards analysis....
<h3>Background</h3> Immune checkpoint inhibitors (ICI) have changed the paradigm of advanced malignant melanoma (MM). Several prognostic factors, mostly linked to inflammation, been under scope better select patients for such therapies. We aimed build and apply a score in this setting. <h3>Methods</h3> Baseline characteristics outcomes on 147 with MM treated an anti-PD1 (nivolumab or pembrolizumab) monotherapy, between Jan-2016 Oct-2019, 1st, 2nd 3rd line setting were collected from two...